劉景晶檢視原始碼討論檢視歷史
| 劉景晶 | |
|---|---|
|
中國藥科大學生命科學與技術學院副院長 | |
| 出生 |
1957年2月 福建 |
| 逝世 | 2011年7月29號 |
| 國籍 | 中國 |
| 職業 | 教育科研工作者 |
劉景晶，1957年2月-2011年7月，福建人，博士，教授，博士生導師[1]，中國藥科大學生命科學與技術學院副院長[2]，美國眼科學會會員。曾被評為江蘇省"六大"人才高峰人選，江蘇省"333"工程第二層次人選，校跨世紀學術帶頭人[3]。2011年7月29號底因肝癌病逝。
主要研究
(1)在美國North Texas大學醫學中心做博士後工作期間，在世界上首次從人視網膜發現了一種新型血管內皮生長因子-VEGF183，基因序列首先在國際基因庫登錄，並於1999年在Invest Ophthalmol Vis Sci.以第一作者發表(IF5.2)。
(2)以劉景晶為主完成的抗癌藥-門冬酰胺酶，已收載於2000年版中國藥典，榮獲江蘇省科技進步二等獎(排名第一)。以劉景晶為主完成的"酶法生產丙氨酸"項目也在省內企業實現了產業化生產，獲得國家醫藥總局科技進步二等獎;完成了"用基因工程菌酶法生產D-對羥基苯甘氨酸"通過了江蘇省科技廳組織的專家鑑定(蘇科鑒字[2002]第321號; 排名第一)。
(3) 在技術創新方面，在國內外首次提出了"微基因藥學"的學科設想，沿該研究思路開展了與重大疾病相關的一系列微基因藥學相關技術研究，完成了微基因藥物製備技術平台研究的"863"項目，建立了"微基因藥學"相關的技術平台，並被學校確立為"211"工程重點支持的研究方向。
(4) 建立的以微基因藥物為研究方向的研究團隊承擔了多項國家"863"計劃課題、國家自然科學基金課題和江蘇省自然科學基金項目，研究方向主要有治療糖尿病的重組人胰島素類等肽類藥物、抗腫瘤生長的核酸疫苗和蛋白質類疫苗、抗動脈粥樣硬化蛋白質藥物和疫苗、抗骨質疏鬆症的小肽類藥物甲狀旁腺素類似物等，研究經費達170萬多元。
(5)申請並公開的國家專利25項;在國內外核心學術期刊上發表各類論文150多篇，其中SCI論文40多篇，多篇論文在J Immunol(IF 6.293)、J Biol Chem(IF 5.808)、Invest Ophthalmol Vis Sci(IF 5.2)Endocr Relat Cancer(IF 5.2)、Vaccine(IF 3.159)等國際著名學術雜誌上刊登，影響因子超過90。
(6)在科研成果的轉化方面，由劉景晶為主完成的抗癌藥門冬酰胺酶已經在江蘇省內企業――常州千紅生化製藥廠生產，產品已經在國內各個大醫院使用，並已經出口到印度等國家，已經創造經濟效益幾千萬元,該產品曾經獲得江蘇省科技進步二等獎;由劉景晶為主完成的"酶法生產丙氨酸"項目也在省內企業實現了產業化生產，獲得原國家醫藥總局科技進步二等獎;完成了"用基因工程菌酶法生產D-對羥基苯甘氨酸"通過了江蘇省科技廳組織的專家鑑定(排名第一)。
個人榮譽
曾多次承擔國家"863"計劃課題、國家自然科學基金課題，目前領導的團隊仍有四項國家自然科學基金項目和兩項省自然科學基金項目，研究經費共計140萬多元。
學術論文
劉景晶教授近年發表的主要SCI論文
[1] Yong Lu, Didier Mekoo, OuyanKedong, XiangbingHu, Yanhua Liu, Ming Lin, Liang Jin, Rongyue Cao, Taiming Li, Zhang Yankai, Hao Fan and Liu Jingjing*.Strong humoral response elicited by a DNA vaccine targeting gastrin-releasing peptide with optimized adjuvants inhibits murine prostate carcinoma growth in vivo.Endocrine-Related Cancer.DOI: 10.1677/ERC-09-0058.
[2] L Yong, Z Huiyong, F Jing, W Huaqian, Y Kejun, Y Yanan, L Suli, W Xuejun, M Yuhan, C Rongyue, F Hao, L Taiming*, andL Jingjing*.Study on preparation and unique properties of a novel insulin analogue with N-terminal Arg-4, Pro-3, Lys-2, Pro-1extension at insulin B-chain.Regulatory Peptides, Oct 2009; 157(1-3): 92-8.
[3] Yong Lu, Jing Fang, KedongOuyang, Guojun Wu, Huiyong Zhang, Yanhua Liu, Yingying Chen, Ming Lin, Huaqian Wang, Liang Jin, Rongyue Cao, Rouel S. Roque, Li Zong, JingjingLiu,* and Taiming Li*. (Lu Yong and Fang Jing contributed equally to this paper). Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo. ClinVaccineImmunol, July 2009, p.1033-1039, Vol. 16, No. 7
[4] Y Lu, K Ouyang, J Fang, H Zhang, G Wu, Y Ma, Y Zhang, X Hu, L Jin, R Cao, H Fan, T Li, and J Liu*. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope, Vaccine, Aug 2009; 27(39): 5411-8.
[5]Jiao Feng, Yanhua Liu, Yun Xing, Huaqian Wang, Taiming Li, JingjingLiu, Hao Fan, Rongyue Cao *.A novel human parathyroid hormone (1-34) analog for the treatment of Osteoporosis. Peptides. DOI:10.1016/j.peptides.2009.02.013.
[6]Yunxiao, Sun; Zhufang, Li; Xin, Yang; Jun, Long; Qiyan, Xiong; Gaofu, Qi; Rongyue, Cao; Jie, Wu; Jingjing, Liu; Hao, Fan; Taiming, Li. Construction, Expression,Purification and Immunology Effect of an AntiatherosclerosisChimeric Enzyme Vaccine in Escherichia coli. [J]Protein & Peptide Letters, 2008, 15, 745-752
[7] QiyanXiong, Jianping Li, Liang Jin, JingjingLiu, Taiming Li*. Nasal mmunization with heat shock protein 65 attenuates atherosclerosis and reduces serum lipids in cholesterol-fed wild-type rabbits probably through different mechanisms. Immunology Letters.DOI:10.1016/j.imlet.2009.05.007.
[8] XiongQiyan, Jin Liang, Li Jianping, Fan Hao, Cao Rongyue, Wu Jie, Li Taiming and Liu Jingjing*. A Th2 immune shift to heat shock protein 65 fails to arrest atherosclerosis :Proatherogenic role of Th2-deviated Autoantibodies. Autoimmunity. DOI: 10.1080/08916930902887086.
[9] Liang J, Aihua Z, Yu W,JingjingL*.Enhanced Immunogenicity of Peptide P277 by Heat Shock Protein HSP65 Vector Carrying Tandem Repeats of P277 to Prevent Type 1 Diabetes in NOD Mice[J]. Exp ClinEndocrinolDiabetes. 2008;116:541-548.
[10]Guojun W, Wei G, Kedong O, Yi H, Yanfei X, Qingmei C, Yankai Z, Jie W, Hao F, Taiming L, JingjingL, Rongyue C. A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo. EndocrRelatCancer, 2008,15(1):149-59
[11] Jin L, Zhu A, Wang Y, Chen Q, Xiong Q, Li J, Sun Y, Li T, Cao R, Wu J, Liu J. A Th1-recognized peptide P277, when tandemly repeated, enhances a Th2 immune response toward effective vaccines against autoimmune diabetes in nonobese diabetic mice. J Immunol, 2008,180(1):58-63
[12] Xu J, Zhu Z, Wu J, Liu W, Shen X, Zhang Y, Hu Z, Zhu D, Roque RS, Liu J. Immunization with a recombinant GnRH vaccine conjugated to heat shock protein 65 inhibits tumor growth in orthotopic prostate cancer mouse model. Cancer Lett, 2008,259(2):240-50
[13] Zhang Y, Xu J, Zhao R, Liu J. Wu J.Inhibition effects on liver tumors of BALB/c mice bearing H22 cells by immunization with a recombinant immunogen of GnRH linked to heat shock protein 65. Vaccine, 2007,25(39-40):6911-21
[14]Chunxiao W, JingjingL. Yire X, Min D, Zhaohui W, Gaofu Q, Xiangchun S, Xuejun W, Jie W, Taiming L. Study on preparation and activity of a novel recombinant human parathyroid hormone (1-34) analog with N-terminal Pro-Pro extension.RegulPept, 2007,141(1-3):35-43
[15] Jin L, Wang Y, Xiong Q, Chen Q, Li J, Zhu A, Cao R, Wu J, Liu J. Long-lasting specific antibodies against P277 induced by mucosal administration of P277 repeat sequences carried by Hsp65 in the absence of adjuvants.Vaccine, 2007,25 (11):2043-50
[16] Xu J, Zhu Z, Duan P, Li W, Zhang Y, Wu J, Hu Z, Roque RS,Liu J. Cloning, expression, and purification of a highly immunogenic recombinant gonadotropin-releasing hormone(GnRH) chimeric peptide. Protein ExprPurif, 2006,50(2):163-70
[17] Xu J, Li W, Wu J, Zhang Y, Zhu Z, Liu J, Hu Z. Stability of plasmid and expression of a recombinant gonadotropin-releasing hormone(GnRH) vaccine in Escherichia coli.ApplMicrobiolBiotechnol, 2006,73(4):780-8
[18] Yankai Z, Rong Y, Yi H, Wentao L, Rongyue C, Ming Y, Taiming L, JingjingL, Jie W. Ten tandem repeats of beta-hCG 109-118 enhance immunogenicity and anti-tumor effects of beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. BiochemBiophysRes Commun, 2006,345(4):1365-71
[19] Mao D, Kai G, Gaofu Q, Zheng Z, Li Z, Jie W, JingjingL, Rongyue C. Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis.Vaccine, 2006,24(23):4942-50
[20] Gaofu Q, Rongyue C, Dan M, Xiuyun Z, Xuejun W, Jie W, JingjingL. Asparaginase display of human cholesteryl ester transfer protein(CETP) B cell epitopes for inducing high titers of anti-CETP antibodies in vivo. Protein PeptLett, 2006,13(2):149-54
[21] Tang SS, Du MH, Zhang XW, Zhang JH, Wu J, Mahanmad E, Liu JJ. A novel hGHRH analog and its comparative activity.Comb ChemHigh Throughput Screen, 2006,9(3):197-20
[22] Yi H, Rong Y, Yankai Z, Wentao L, Hongxia Z, Jie W, Rongyue C, Taiming L, JingjingL. Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Vaccine, 2006,24(14):2575-84
[23] Jinshu X, JingjingL, Duan P, Zheng Z, Ding M, Jie W, Rongyue C, Zhuoyi H, Roque RS. A synthetic gonadotropin-releasing hormone(GnRH) vaccine for control of fertility and hormone dependent diseases without any adjuvant.Vaccine, 2005,23 (40):4834-43
[24] Gaofu Q, Jun L, Xiuyun Z, Wentao L, Jie W, JingjingL. Antibody against cholesteryl ester transfer protein(CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model. Life Sci, 2005,77(21):2690-70
[25] Gaofu Q, Jie L, Rongyue C, Xin Y, Dan M, Jie W, Xiangchun S, Qunwei X, Roque RS, Xiuyun Z, JingjingL. Asparaginase display of polypeptides in the periplasm of Escherichia coli: potential rapid pepscan technique for antigen epitope mapping. J ImmunolMethods, 2005,299(1-2):9-19
[26] Gaofu Q, Jun L, Xin Y, Wentao L, Jie W, Xiuyun Z, JingjingL. Vaccinating rabbits with a cholesteryl ester transfer protein(CETP) B-Cell epitope carried by heat shock protein-65(HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo. J CardiovascPharmacol, 2005,45(6):591-8
[27] Gaofu Q, Dan M, Jie W, Liao Z, Li Z, Roque RS, JingjingL. Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants. Vaccine, 2004,22(23-24):3187-94
[28] Jinshu X, JingjingL, Duan P, Zheng Z, Ding M, Jie W, Rongyue C, Zhuoyi H. The immunogenicity of recombinant and dimericgonadotrophin-releasing hormone vaccines incorporating a T-helper epitope and GnRH or repeated GnRH units.JImmunolMethods, 2004,289(1-2):111-22
[29]Gaofu Q, Jie W, Xin Y, Roque RS, JingjingL. Expressing and purifying an anti-atherosclerosis polypeptide vaccine in Escherichia coli. ProteinExprPurif, 2004,36(2):198-206
[30] Tang SS, Zhang JH, Du MH, Wu J, Liu JJ. Construction and activity of a novel GHRH analog, Pro-Pro-hGHRH(1-44)-Gly-Gly-Cys. ActaPharmacolSin, 2004,25(11):1464-70
[31] Tang SS, Chen ZL, Liu JJ. Production and enhanced biological activity of a novel GHRH analog, hGHRH with an N-terminal Pro-Pro extension.Protein ExprPurif, 2004,34(2):296-301
[32] Evert BA, Salmon TB, Song B, JingjingL, Siede W, Doetsch PW. Spontaneous DNA damage in Saccharomycescerevisiae elicits phenotypic properties similar to cancer cells.J BiolChem, 2004,279(21):22585-94
[33] Yuehua L, Jing G, Kai F, Hongwei W, JingjingL. Left atrialmyxoma presenting with erythematousmacules and loss of memory. ClinExp Dermatol, 2003,28(4):383-6
[34] Zhang Y, Taiming L, Liu J. Low temperature and glucose enhanced T7 RNA polymerase-based plasmid stability for increasing expression of glucagon-like peptide-2 in Escherichia coli. Protein ExprPurif, 2003,29(1):132-9
[35] Tan S, Wu W, Liu J, Kong Y, Pu Y, Yuan R. Efficient expression and secretion of recombinant hirudin III in E. coli using the L-asparaginase II signal sequence. Protein ExprPurif, 2002,25(3):430-6
[36] Ming Xin, Yang Li, Lin Jie, Ding Min and JingjingLiu. An X-ProlylDipeptidylAminopeptidase from Lactococcuslactis: Cloning, Expression in Escherichia coli, and Application for Removal of N-Terminal Pro-Pro from Recombinant Proteins. Protein ExprPurif, 2002,2(3):530-8
[37] JingjingL, Srinivasan B, Roque RS. Ectodomain shedding of VEGF183, a novel isoform of vascular endothelial growth factor, promotes its mitogenic activity in vitro. Angiogenesis, 2001,4(2):103-12
[38]JingjingL, Srinivasan B, Bian X, Downey HF, Roque RS. Vascular endothelial growth factor is increased following coronary artery occlusion in the dog heart. Mol Cell Biochem, 2000,214(1-2):23-30
[39]JingjingL, Xue Y, Agarwal N, RoqueRSHumanMüller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest OphthalmolVis Sci, 1999,40(3):752-9
[40]Roque RS, Rosales AA, JingjingL, Agarwal N, Al-UbaidiMRRetina-derived microglial cells induce photoreceptor cell death in vitro. Brain Res, 1999,836 (1-2):110-9
[41]Harold J，Sheedlo，RaghuKrishnamoorthy，Tammy Nelson，NeerajAgarwal，Jingjing Liu，Rouel S. Roque，Robert J Retina-derived fetuin (RDF): Analysis by immunocytochemistry, reverse transcriptase-polymerase chain reaction and Southern blotCurrent Eye Research, 1999，19(6), 465-71
所建實驗室
劉景晶教授建立的微基因藥物實驗室
劉景晶教授建立的實驗室擁有HPLC，毛細管電泳，高速冷凍離心機，酶標儀，5L和50L的發酵罐等多台先進儀器。除了常規實驗室以外，實驗室還配備有專門的動物房和細胞房。目前劉老師領隊的科研團隊主要致力於核酸和多肽類疫苗的研發，包括動脈粥樣硬化，糖尿病，腫瘤等相關疫苗和多肽類生物技術藥物。實驗室擁有二十多個從事分子、生化、免疫、藥理的碩士和博士研究生。
微基因藥物實驗室與企業的成功合作
微基因藥物實驗室還與上海一就生物醫藥有限公司建立了長期的互助合作關係。
上海一就生物醫藥有限公司是一家致力於生物活性肽衍生肽開發和多肽表達技術研究的現代生物技術公司。公司根據現代藥物研發的最新理念和技術，建立了生物活性肽高效表達和大規模製備技術平台。在生物活性肽衍生肽研究和生物活性肽高效率表達等方面處於領先水平。